Related Experiment Videos
Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes
Alan J Garber1, Daniel S Donovan, Paresh Dandona
1Baylor College of Medicine and the Methodist Hospital, Houston, Texas 77030, USA. agarber@bcm.tmc.edu
Abstract:
Many patients with type 2 diabetes fail to achieve or maintain the American Diabetes Association's recommended treatment goal of glycosylated hemoglobin levels. This multicenter, double-blind trial enrolled patients with type 2 diabetes who had inadequate glycemic control [glycosylated hemoglobin A(1C) (A1C), >7% and <12%) with diet and exercise alone to compare the benefits of initial therapy with glyburide/metformin tablets vs. metformin or glyburide monotherapy. Patients (n = 486) were randomized to receive glyburide/metformin tablets (1.25/250 mg), metformin (500 mg), or glyburide (2.5 mg). Changes in A1C, fasting plasma glucose, fructosamine, serum lipids, body weight, and 2-h postprandial glucose after a standardized meal were assessed after 16 wk of treatment. Glyburide/metformin tablets caused a superior mean reduction in A1C from baseline (-2.27%) vs. metformin (-1.53%) and glyburide (-1.90%) monotherapy (P = 0.0003). Glyburide/metformin also significantly reduced fasting plasma glucose and 2-h postprandial glucose values compared with either monotherapy. The final mean doses of glyburide/metformin (3.7/735 mg) were lower than those of metformin (1796 mg) and glyburide (7.6 mg). First-line treatment with glyburide/metformin tablets provided superior glycemic control over component monotherapy, allowing more patients to achieve American Diabetes Association treatment goals with lower component doses in drug-naive patients with type 2 diabetes.
Insights
Initial therapy with glyburide/metformin tablets offers superior glycemic control for type 2 diabetes patients compared to monotherapy. This combination therapy helps more patients reach treatment goals with lower doses.
Area of Science:
- Endocrinology
- Pharmacology
- Clinical Medicine
Background:
- Many type 2 diabetes patients struggle to meet glycemic targets set by the American Diabetes Association.
- Inadequate glycemic control increases the risk of long-term diabetes complications.
Purpose of the Study:
- To compare the efficacy of initial glyburide/metformin tablet therapy versus metformin or glyburide monotherapy in type 2 diabetes patients.
- To evaluate the impact of combination therapy on glycosylated hemoglobin A1C (A1C) and other glycemic markers.
Main Methods:
- A multicenter, double-blind trial randomized 486 type 2 diabetes patients with A1C between 7% and 12% to receive glyburide/metformin tablets, metformin, or glyburide monotherapy.
- Assessments included A1C, fasting plasma glucose, fructosamine, lipids, body weight, and postprandial glucose after 16 weeks.
Main Results:
- Glyburide/metformin tablets achieved a superior mean A1C reduction (-2.27%) compared to metformin (-1.53%) and glyburide (-1.90%) monotherapy (P = 0.0003).
- Combination therapy significantly lowered fasting plasma glucose and 2-h postprandial glucose levels more effectively than monotherapy.
- Effective glycemic control was achieved with lower final mean doses of glyburide/metformin compared to monotherapy components.
Conclusions:
- First-line treatment with glyburide/metformin tablets provides superior glycemic control in drug-naive type 2 diabetes patients.
- This combination therapy enables more patients to achieve American Diabetes Association treatment goals.
- Initial combination therapy allows for lower component drug doses while enhancing efficacy.